Status:
COMPLETED
Cystic Fibrosis (CF) Leukocyte Genes as Biomarkers for Novel Therapies
Lead Sponsor:
National Jewish Health
Collaborating Sponsors:
Cystic Fibrosis Foundation
Conditions:
Cystic Fibrosis
Pulmonary Exacerbation
Eligibility:
All Genders
18+ years
Brief Summary
Presently, effectiveness of treatments for CF lung disease is judged by improvement in lung function (FEV1). However, in CF patients, FEV1 can range from severely decreased to normal, and improvements...
Eligibility Criteria
Inclusion
- Documented diagnosis of CF.
- Age 18 years old or greater.
- Presentation at the start of treatment for a pulmonary exacerbation of CF.
- Ability to perform reproducible Pulmonary Function Tests.
- Willingness to comply with study procedure and willingness to provide written consent.
Exclusion
- Participation in an investigational drug study within one month of enrollment.
- Presence of a condition or abnormality that, in the opinion of the Principal Investigator (PI), would compromise the safety of the patient or the quality of the data.
Key Trial Info
Start Date :
February 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 1 2012
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT00727285
Start Date
February 1 2008
End Date
October 1 2012
Last Update
March 29 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Jewish Health
Denver, Colorado, United States, 80206